Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure

Research output: Contribution to journalReview article

350 Scopus citations

Abstract

Acetaminophen overdose is the leading cause for calls to Poison Control Centers (>100,000/year) and accounts for more than 56,000 emergency room visits, 2,600 hospitalizations, and an estimated 458 deaths due to acute liver failure each year. Data from the U.S. Acute Liver Failure Study Group registry of more than 700 patients with acute liver failure across the United States implicates acetaminophen poisoning in nearly 50% of all acute liver failure in this country. Available in many single or combination products, acetaminophen produces more than $1 billion dollars in annual sales for Tylenol products alone. It is heavily marketed for its safety compared to nonsteroidal analgesics. By enabling self-diagnosis and treatment of minor aches and pains, its benefits are said by the Food and Drug Administration to outweigh its risks. It still must be asked: Is this amount of injury and death really acceptable for an over-the-counter pain reliever?

Original languageEnglish (US)
Pages (from-to)6-9
Number of pages4
JournalHepatology
Volume40
Issue number1
DOIs
StatePublished - Jul 1 2004

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure'. Together they form a unique fingerprint.

  • Cite this